The U.S. Food and Drug Administration has accepted Novartis AG (NOVN.VX) unit Sandoz’s regulatory submission for approval of a biosimilar to Amgen Inc’s (AMGN.O) blockbuster Enbrel drug, the Swiss drugmaker said on Friday. Etanercept, the drug’s generic name, is a tumor necrosis factor alpha (TNF-alpha) inhibitor. Sandoz is seeking approval for all indications included in the label of the reference product, which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis, it said in a statement.